Search Results - "Inglis, Daniel"

The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer by Inglis, Daniel J, Lavranos, Tina C, Beaumont, Donna M, Leske, Annabell F, Brown, Chloe K, Hall, Allison J, Kremmidiotis, Gabriel

“…BNC105 is a tubulin targeting compound that selectively disrupts vasculature within solid tumors. The severe tumor hypoxia and necrosis that ensues translates…”
Get full text

Circulating tumour cell RNA characterisation from colorectal cancer patient blood after inertial microfluidic enrichment by Winter, Marnie, Cai, Zhen, Winkler, Katharina, Georgiou, Kristen, Inglis, Daniel, Lavranos, Tina, Rezaei, Meysam, Warkiani, Majid, Thierry, Benjamin

“…[Display omitted] The detection and molecular analysis of circulating tumour cells (CTCs) potentially provides a significant insight to the characterisation of…”
Get full text

Abstract 4695: Targeting the LGR5 complex with BNC101 to improve checkpoint inhibitor therapy in colorectal cancer by Inglis, Daniel J., Beaumont, Donna M., Lavranos, Tina C.

“…LGR5 is a well characterised marker of intestinal stem cells found at the base of intestinal crypts and a receptor for R-spondins, potent Wnt signalling…”
Get full text

Abstract 4982: BNC105 induces tumor micro-environment changes which enhance the efficacy of checkpoint inhibitor therapy in preclinical models by Inglis, Daniel J., Beaumont, Donna M., Leske, Annabell F., Scherer, Michaela A., Lavranos, Tina C.

“…BNC105 is a Phase II stage drug that specifically targets tubulin causing rapid depolymerisation. The therapeutic window of BNC105 has been shown to be…”
Get full text

Abstract 3910: Characterization of BNC101 a human specific monoclonal antibody targeting the GPCR LGR5: First-in-human evidence of target engagement by Inglis, Daniel J., Licari, John, Georgiou, Kristen R., Wittwer, Nicole L., Hamilton, Ross W., Beaumont, Donna M., Scherer, Michaela A., Lavranos, Tina C.

“…At the base of normal intestinal crypts, stem cells maintain the highly regenerative gut epithelium. These intestinal stem cells are well characterized for…”
Get full text

Abstract 1881: The microtubule-disrupting drug BNC105 is a potent inducer of apoptosis in AML patient samples by Inglis, Daniel J., Casolari, Debora A., Nguyen, Tran, Beaumont, Donna M., Wittwer, Nicole L., Ross, David, D'Andrea, Richard, Lavranos, Tina C.

“…BNC105 is a phase II potent and highly selective disruptor of tumor microvasculature that causes the rapid onset of hypoxia and necrosis in solid tumors…”
Get full text

Abstract B92: The tubulin-targeting agent BNC105 potentiates the efficacy of immune checkpoint inhibitors in preclinical models of colorectal cancer by Lavranos, Tina C., Beaumont, Donna, Inglis, Daniel, Scherer, Michaela, Hawkins, Chloe, Leske, Annabell F., Kremmidiotis, Gabriel

“…BNC105 is a tubulin depolymerisation agent. Its activity includes effects on both cancer cells and on solid tumor microvasculature. BNC105 shows evidence of…”
Get full text

Abstract 4115: BNC420 is a novel VEGFR3 selective inhibitor, which unlike the pan-VEGFR inhibitor Sunitinib, suppresses lymphatic metastasis in a model of metastatic melanoma by Leske, Annabell, Lavranos, Tina, Beaumont, Donna, Brown, Chloe, Paul, Darham, Inglis, Daniel, Scherer, Michaela, Harvey, Andrew, Kremmidiotis, Gabriel

“…The dissemination of cancer cells through the lymphatic system is a well-known route of metastasis. Studies have implicated the hypoxic tumor microenvironment…”
Get full text

Abstract B174: Complementary activity of the vascular disruption agent BNC105 and the hypoxia-activated prodrug evofosfamide (TH-302) in suppressing the growth of preclinical renal and breast solid tumors by Lavranos, Tina C., Inglis, Daniel, Beaumont, Donna, Leske, Annabell F., Hawkins, Chloe, Scherer, Michaela, Hart, Charles, Sun, Jessica, Elenbaas, Brian, Kremmidiotis, Gabriel

“…BNC105 is a vascular disruption agent that selectively disrupts tumor blood vessels resulting in hypoxia and necrosis. Evofosfamide (previously known as…”
Get full text

Abstract B67: Induction of tumor hypoxia synergises with inhibitors of tumor metabolic and angiogenic adaptive responses to suppress tumor growth and enhance host survival by Inglis, Daniel J., Lavranos, Tina C., Beaumont, Donna M., Leske, Annabell F., Brown, Chloe K., Kremmidiotis, Gabriel

“…BNC105 is a compound that exerts an anti-cancer action through selective destruction of tumor blood vessels. A single IV dose of BNC105 causes a very high…”
Get full text

Abstract 4039: Harnessing the tumor adaptive response to hypoxia to identify novel combinations of the vascular disrupting agent BNC105 with targeted therapeutics by Lavranos, Tina C., Inglis, Daniel J., Beaumont, Donna M., Leske, Annabell F., Brown, Chloe K., Kremmidiotis, Gabriel

“…BNC105 is a small molecule Vascular Disrupting Agent (VDA) that exerts anti-cancer activity through selective shut-down of tumor blood vessels. A single dose…”
Get full text

Abstract 2774: Anti-cancer activity of the tumor-selective, hypoxia-inducing, agent BNC105 in platinum resistant ovarian cancer by Lavranos, Tina C., Leske, Annabell F., Inglis, Daniel J., Brown, Chloe K., Bibby, David C., Kremmidiotis, Gabriel

“…BNC105 is a small molecule that exerts anti-cancer activity through disruption of tubulin polymerization. BNC105 is unique in its ability to selectively block…”
Get full text

Abstract 4029: BL-011256 is a novel VEGFR3 selective inhibitor, which suppresses tumor lymphatics and lymph node metastasis in an animal model of melanoma by Leske, Annabell, Foitzik, Richard, Beaumont, Donna, Bentley, John, Bergman, Ylva, Brown, Chloe, Camerino, Michelle, Charman, Susan, Choi, Neil, Silva, Melanie D., Chung, Matthew, Falk, Hendrik, Ganame, Danny, Gregg, Alison, Grusovin, Julian, Harvey, Andrew, Hemley, Catherine, Holmes, Ian, Huff, Belinda, Inglis, Daniel, Kersten, Wilhelmus, Lavranos, Tina, Lessene, Romina, Lunniss, Gillian, Monahan, Brendon, Morrow, Benjamin, Nikac, Marica, Nikolakopoulos, George, Paul, Dharam, Peat, Tom, Ripper, Justin, Scherer, Michaela, Stupple, Paul, White, Karen, Street, Ian, Kremmidiotis, Gabriel

“…The role of VEGFR3 in lymphangiogenesis has been well established. Targeting VEGFR3 has been shown to curtail tumor progression mediated via lymphatic…”
Get full text